Nav1.5 Ser571 Phosphorylation, Late Sodium Current, and Cardiac Aging: Mechanisms and Implications

Study Background and Research Question

Aging is the predominant independent risk factor for chronic heart failure and is accompanied by a marked increase in cardiovascular disease incidence. In elderly individuals, diastolic dysfunction and delayed ventricular repolarization are well-documented, but the molecular mechanisms underlying these age-related changes remain incompletely defined. The reference study addresses whether the progressive dysfunction seen in aging myocardium is causally linked to alterations in the late sodium current (INa,L) and, specifically, the phosphorylation state of the cardiac sodium channel Nav1.5 at Ser571.

Key Innovation from the Reference Study

The central innovation of this study is the direct demonstration that phosphorylation of Nav1.5 at Ser571 acts as an early molecular switch that anticipates and drives the electrophysiological and mechanical manifestations of the aging heart. By employing genetically engineered mouse models with either phosphomimetic (gain-of-function, GoF) or phosphoablated (loss-of-function, LoF) mutations at Ser571, the authors elucidate how increased INa,L due to Nav1.5 phosphorylation prolongs action potential duration and impairs diastolic left ventricular filling. This work bridges a critical gap between sodium channel post-translational modification and age-dependent cardiac decline, suggesting that targeting INa,L may mitigate age-associated arrhythmogenic and mechanical dysfunction.

Methods and Experimental Design Insights

The investigators utilized a combination of in vivo and in vitro cardiac electrophysiology to dissect the role of Nav1.5 Ser571 phosphorylation in age-related cardiac remodeling. Key methodological elements included:

• Comparative analysis of male and female wild-type (WT) C57Bl/6 mice across adult (3–5 months), middle-aged, and aged (18–30 months) timepoints.
• Use of knock-in mouse lines harboring either phosphomimetic (Ser571Asp, GoF) or phosphoablated (Ser571Ala, LoF) mutations in Nav1.5 to model persistent versus stabilized INa,L.
• Electrocardiographic measurement of QT interval duration and echocardiographic assessment of diastolic function.
• Patch-clamp recordings from isolated ventricular myocytes to quantify late sodium current and action potential duration (APD90).
• Calcium transient kinetics and contractile function assessment in single cardiomyocytes to determine the impact of altered INa,L on excitation-contraction coupling.

Pharmacological inhibition of late sodium current was also performed in aged WT mice to directly test the reversibility of observed phenotypes.

Core Findings and Why They Matter

The study reports several pivotal findings:

• Aging WT mice exhibit a ~60% increase in INa,L and a ~50% prolongation of APD90 compared to young adults, corroborating previous reports of age-related electrical remodeling (see related summary).
• Prolonged ventricular repolarization and impaired diastolic left ventricular filling develop in WT mice after 18 months, but these defects occur much earlier in GoF mice and are markedly attenuated in LoF mutants.
• GoF mice demonstrate premature onset of delayed Ca2+ transient decay and myocyte relaxation abnormalities, mirroring the phenotypes of aged WT hearts. In contrast, LoF mice largely preserve myocardial relaxation and repolarization profiles even at advanced ages.
• Acute inhibition of INa,L in aged WT mice rapidly normalizes QT interval and improves diastolic filling, directly linking late sodium current to the observed dysfunction.

Together, these results establish that Ser571 phosphorylation of Nav1.5 is both necessary and sufficient to drive maladaptive increases in late sodium current, implicating this pathway as a prime target for interventions seeking to improve cardiac function and reduce arrhythmogenic risk in aging populations. This mechanistic insight underscores the translational potential of selective late sodium current inhibition in models of cardiac aging and disease.

Comparison with Existing Internal Articles

The findings of the reference study are consistent with and extend prior literature on late sodium current inhibitors in aging and arrhythmia models. For example, the internal review "GS967: Advanced Cardiac Late Sodium Current Inhibitor in Research" highlights the unique selectivity and potency of GS967 as a tool for dissecting arrhythmogenic mechanisms in aged and stressed myocardium. That article details how GS967-mediated inhibition of INa,L enables high-fidelity in vitro cardiac electrophysiology and arrhythmia prevention research, supporting the translational application of the molecular insights gained in the reference study.

Similarly, the summary "Nav1.5 Ser571 Phosphorylation Drives Cardiac Aging Phenotypes" contextualizes Ser571 phosphorylation as a nodal event in cardiac aging, reinforcing the idea that targeted INa,L inhibition may interrupt the progression of age-related electrophysiological and mechanical dysfunction. The workflow-oriented piece "GS967: Cardiac Late Sodium Current Inhibitor for Aging Models" describes experimental protocols for integrating GS967 into arrhythmia prevention and aging studies, providing practical guidance that aligns with the mechanistic rationale elucidated in the 2024 reference article.

Limitations and Transferability

While the study offers compelling evidence for the causal role of Nav1.5 Ser571 phosphorylation and late sodium current in aging myopathy, a few limitations merit consideration:

• Mouse models recapitulate many aspects of human cardiac aging, but species-specific differences in sodium channel regulation and cardiac electrophysiology may influence transferability to human disease.
• The study focuses on isolated genetic and pharmacological perturbations of INa,L; the interplay with other aging-associated pathways (fibrosis, inflammation, autonomic remodeling) requires further investigation.
• Acute pharmacological interventions are informative but may not fully predict long-term efficacy or safety of chronic late sodium current inhibition in elderly patients.

Nevertheless, the robust experimental design and consistency with prior in vitro and in vivo studies strengthen the relevance of these findings for translational arrhythmia prevention research and the development of targeted interventions for aging-related cardiac dysfunction.

Protocol Parameters

• Late Na+ current measurement: Employ patch-clamp recordings from ventricular myocytes, measuring INa,L amplitude at 90% repolarization (APD90), as outlined in the reference study; compare aged (18–30 months) and young (3–5 months) cohorts.
• Pharmacological inhibition: Apply a selective cardiac late sodium current inhibitor at concentrations validated in the literature (e.g., GS967 at 0.13 µM in ventricular myocytes, per product information), and assess acute effects on QT interval and diastolic function.
• Genetic modeling: Utilize knock-in mouse lines with targeted mutations at Nav1.5 Ser571 to simulate gain- or loss-of-function INa,L phenotypes and evaluate age-dependent cardiac remodeling.
• Myocyte mechanics: Quantify Ca2+ transient decay and relengthening kinetics in isolated cardiomyocytes to link electrical alterations with contractile function.

Research Support Resources

To facilitate advanced in vitro cardiac electrophysiology studies and arrhythmia prevention research in aging or disease models, researchers can integrate GS967 (SKU B5850), a potent and selective cardiac late sodium current inhibitor. According to the product information, GS967 enables reproducible inhibition of INa,L, supporting translational workflows that build on the mechanistic framework established in the reference study. For protocol optimization and troubleshooting, several internal reviews also provide detailed guidance on GS967’s application in arrhythmia and aging models. As always, GS967 is for research use only and should be handled in accordance with recommended storage and safety practices.